Evaluation of a New CZT System

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
First received: March 9, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted

The purpose of the study is to check if the new CZT system has an advantage in detection of small osseous processes, thyroid adenomas, parathyroid adenomas and detection of sentinel node, in comparison with the techniques in use.

Participants: 100 subjects male and female that come to the institute of nuclear medicine for routine screening examinations.

The CZT screening takes 10 minutes and does not require any extra intervention to the routine screening.

Parathyroid Adenoma
Thyroid Adenoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment: 100
Study Start Date: March 2010
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
patients admitted for Tc thyroid scan
patients investigated for parathyroid adenoma
sentinel node
patients who are due to sentinel node biopsy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
consequtive patiants admitted for the above scans and consented to be further investigated by the CZT system

Inclusion Criteria:

  • age over 18

Exclusion Criteria:

  • pregnancy
  • patients unable to understand and sign an informed consent
  • age under 18
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01084356

Contact: Einat Even Sapir, PhD,MD 972-3-6974444 ext 3536 evensap@tasmc.health.gov.il
Contact: Ayelet Kurzband, BA 972-3-6974444 ext 3536 ayeletk@tasmc.health.gov.il

Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel
Contact: Einat Even Sapir, PhD, MD    972-3-6974444 ext 3536    evensap@tasmc.health.gov.il   
Contact: Ayelet Kurzband, BA    972-3-6974444 ext 3536    ayeletk@tasmc.health.gov.il   
Sub-Investigator: Hedva Lerman, MD         
Principal Investigator: Einat Even-Sapir, MD, PhD         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Einat Even Sapir, PhD, MD Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  More Information

Responsible Party: Einat Even-Sapir MD, PhD. Head, Dept of Nuclear Medicine, Tel Aviv SoUrasky medical center
ClinicalTrials.gov Identifier: NCT01084356     History of Changes
Other Study ID Numbers: TASMC-10-EES-0649-CTIL 
Study First Received: March 9, 2010
Last Updated: March 9, 2010
Health Authority: Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:
sentinel node
osseous processes

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on April 27, 2016